BIOJECT APPOINTS PRESIDENT OF JOINT VENTURE WITH ELAN;

  The Company Expands Marketing for Blood Glucose Monitoring System 
PORTLAND, Ore., Nov. 17 /PRNewswire/ -- Bioject Medical Technologies Inc.
(Nasdaq: BJCT), the leading manufacturer of jet injection devices for
needle-free drug delivery, today announced that Bradley J. Enegren, 51, has
been named president and CEO of Marathon Medical Technologies, Bioject's joint
venture with Elan Corporation, plc. (NYSE: ELN).  His responsibilities will be
focused on the research, development and commercialization of an ambulatory,
continuous blood glucose monitoring system for diabetes patients. 
Jim O'Shea, chairman, president and chief executive officer stated, "With
over fifteen years of medical product sales and marketing experience, Brad's
extensive skills and experience, particularly in the medical diagnostic and
therapeutic markets, will greatly enhance the continued success of this
venture.  His contributions will be critical as we proceed with further
clinical testing in 1999 and take initial steps towards global
commercialization." 
Enegren joins Bioject from Arrow International, where he served as
managing director of the Implantable Drug Delivery Division.  While at Arrow,
Enegren was also responsible for the successful acquisitions of implantable
pump product lines from Pfizer Inc. and Therex Corporation.  Prior to joining
Arrow, Enegren was president and managing director of Therex from 1987 to
1995.  His experience also includes two years as director of marketing and
business development for Boston Scientific, Inc.  Enegren began his career
with Corning Glass Works, where he worked from 1976 to 1981 in the company's
Medical & Science Products Division. 
Enegren said, "I'm excited to be working with a team that has the
experience and knowledge necessary to develop and launch an innovative product
like our blood glucose monitor.  I believe the product will have significant
advantages over existing technologies.  This should give us immediate momentum
when we bring the product to the market.  Marathon Medical Technologies
presents a great opportunity for all involved especially for the patients who
have not yet had adequate technologies help them conveniently monitor the
level of glucose in their blood.  Diabetes-related complications costs the
healthcare system nearly $100 billion annually." 
Established in October 1997 as a majority owned subsidiary of Bioject,
Marathon Medical Technologies, based in Worchester, MA, is 80.1 percent owned
by Bioject and 19.9 percent owned by Elan.  In prototype pre-clinical trials
of the product this spring, the disposable patch-like sensor and lightweight
monitoring system tracked the blood glucose levels of six diabetes patients
over 15 hours with significant levels of accuracy.  Based on the results of
continued preliminary clinical studies, Marathon plans to conduct pivotal
clinical trials of the monitoring system in 1999. 
Bioject develops, manufactures and markets jet injection systems for
needle-free subcutaneous and intramuscular injections.  In a joint venture
with Elan Corporation, Bioject is developing an ambulatory, continuous blood
glucose monitoring system for diabetes patients.  The Company's advanced
injection management system, the Biojector 2000, has received the Seal of
Acceptance from the Alliance of Children's Hospitals, Inc. 
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995, including statements
concerning future product development activities and accomplishments and
anticipated market acceptance of products being developed.  Such
forward-looking statements involve known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or achievements
of the company, or industry results, to be materially different from any
future results, performance, or achievements expressed or implied by such
forward looking statements.  Such risks, uncertainties and other factors
include, without limitation, the risk that research and development efforts
will not produce the desired results, uncertainties related to the time
required to complete research and development, uncertainties related to
obtaining necessary clinical data and government clearances, uncertainties
related to market acceptance of products being developed as well as the
products' ability to compete successfully with other products in the market
and the need for additional financing.  Readers of this press release are
referred to the Company's filings with the Securities and Exchange Commission,
including the Company's Annual Report on Form 10-K/A for the year ended
March 31, 1998 and the Company's quarterly report on From 10-Q for the period
ended June 30, 1998 for further discussion of these and other factors which
could affect future results.
 

SOURCE  Bioject Medical Technologies Inc. 
-0-                             11/17/98 
/CONTACT:  Jim O'Shea, Chairman, President & CEO, or Mike Temple,
Vice President & CFO, both of Bioject Medical Technologies Inc., 503-639-7221;
or Heather Regan of Noonan/Russo Communications, Inc., 212-696-4455, ext. 241,
or news@noonanrusso.com/ 
(BJCT ELN) 
CO:  Bioject Medical Technologies Inc.; Marathon Medical Technologies; 
 Elan Corporation, plc
ST:  Oregon, New York, Massachusetts
IN:  MTC
SU:  PER JVN 
-0- Nov/17/1998   16:15
EOS   (PRN)    Nov/17/98    16:15      86
â
-0- (PRN) Nov/17/1998   16:30
 
 
Press spacebar to pause and continue. Press esc to stop.